Replies to post #13986 on NanoLogix Inc (NNLX)

[Omar8]

Oilin07,


"I don't know because if history repeats itself there will be nothing."


I know it sucks, here we are more than 6 months after this below and was it sucessful(?) and after all this time and researching FDA rquirements where are they are they close ?

As More time goes by the more it seems like they doing the same they have done for years.




Oct. 14, 2020

NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent

1st For Whole Virus Detection, 2nd For Antibody Detection

NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development

NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.

Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.

[Omar8]

Oilin07,



The company could surprise us and start moving along quickly with RVA or.......



We could be in a repeat of Pretest with N-Assay...they were getting there and getting there....


Check out this update not too long ago on the Pretest with N-assay, it's 2021 now, will a surprise N-Assay/Pretest update coming ?....sounded like we were moving along...reading the recent RVA update..sounds like moving along too....will they get to the finish line or fizzle ?


"Dec. 16, 2019

NanoLogix Update on Phase One PreTest Development

NanoLogix is pleased to provide an update on the development of a Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.